Next Science (ASX:NXS) PB Ratio: (As of Aug. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:NXS Next Science Ltd ASX:NXS
25 GF Score
Price A$0.15
GF Value A$37.70
! 7 Warning Signs
View Full Analysis

What is Next Science PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-24), Next Science's share price is A$0.145. Next Science's Book Value per Share for the quarter that ended in Jun. 2025 was A$-0.00. Hence, Next Science's PB Ratio of today is .

The historical rank and industry rank for Next Science's PB Ratio or its related term are showing as below:

During the past 7 years, Next Science's highest PB Ratio was 16.67. The lowest was 0.02. And the median was 8.88.

ASX:NXS's PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.96
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, Next Science's average Book Value Per Share Growth Rate was -108.30% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -39.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -32.50% per year.

During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Next Science was -23.20% per year. The lowest was -43.50% per year. And the median was -34.70% per year.

Back to Basics: PB Ratio


Next Science  (ASX:NXS) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Next Science PB Ratio Related Terms


Next Science PB Ratio Historical Data

* Premium members only.

The historical data trend for Next Science's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Next Science PB Ratio Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial 9.69 16.38 12.45 5.15 6.05

Next Science Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 5.15 6.53 6.05 0.00

ASX:NXS vs GCAN, PTPI, GRPS: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Next Science PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's PB Ratio distribution charts can be found below:

* The bar in red indicates where Next Science's PB Ratio falls into.


ASX:NXS
25GF Score
Next Science Ltd ASX:NXS
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Next Science PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Next Science's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2025)
=0.145/-0.003
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is Next Science (ASX:NXS) Overvalued in 2026?

Based on GuruFocus' analysis, Next Science stock appears to be undervalued. The current stock price of A$0.15 is trading 99.6% below its estimated GF Value™ of A$37.70.

Key valuation signals for ASX:NXS:

  • PB Ratio:
  • GF Value™: A$37.70 vs. price of A$0.15 (99.6% below fair value)
  • GF Score™: 25/100 with 7 warning signs

No single metric tells the full story. See the ASX:NXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Next Science Business Description

Address 264-278 George Street, Level 14, Australia Square, HWL Ebsworth, Sydney, NSW, AUS, 2000
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with efficacy in eradicating both biofilm-based and free-floating bacteria. Its products include Bactisure, XEPERIENCE and BLASTX. The company derives revenue from North America, New Zealand, and Australia.
25GF Score

Get the complete analysis for ASX:NXS

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price
A$37.70
GF Value